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Summary
 Background Human adenovirus (HAdV) infections are increasingly recognized as a frequent 
cause of potentially fatal infections in paediatric allogeneic stem cell transplan-
tation (SCT) recipients.
 Aim To analyse data in the ﬁ eld of diagnosis and treatment of human adenovirus in-
fection following allogeneic haematopoietic stem cell transplantation.
 Materials/Methods A review of PubMed references based on evidence-based recommendations and 
own experience.
 Results Incidence of HAdV infections is higher in paediatric than in adult SCT recipi-
ents, which might be related to the high exposure to HAdV at young age, while 
HAdV-speciﬁ c immunity has still to be mounted, especially in children receiv-
ing a T-cell depleted graft and/or a graft of another than an HLA-genotypically 
identical related donor. In subsequent retrospective and prospective studies evi-
dence has been provided that monitoring of serum/plasma by RQ-PCR is a sen-
sitive tool for the recognition of patients at risk of potentially fatal infection, and 
that quantiﬁ cation of HAdV DNA is instrumental to make decisions on clinical 
intervention, and to accurately monitor the response to antiviral therapy. Several 
antiviral drugs (ribavirin and cidofovir) are being used to treat HAdV infections 
and variable efﬁ cacy has been reported. Reports on possible clinical efﬁ cacy of 
drugs are often biased, because of the heterogeneity of patients and lack of infor-
mation about the level of simultaneous immune reconstitution. Data from sever-
al retrospective and prospective studies have demonstrated that lymphocyte re-
covery is essential for the elimination of HAdV infection.
 Conclusions Based on current knowledge, boosting of immunity by tapering of immunosup-
pression or infusion of lymphocytes from the donor seems to be an essential ele-
ment in treatment of patients at risk of HAdV viraemia. Simultaneous analysis of 
lymphocyte reconstitution will further improve the identiﬁ cation of individuals 
that will require and beneﬁ t most from the immunotherapeutic interventions.
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BACGROUND
Human adenovirus (HAdV) infections are in-
creasingly recognized as a frequent cause of 
potentially fatal infections in paediatric alloge-
neic stem cell transplantation (SCT) recipients. 
Currently, 51 serotypes of HAdV are known which 
are grouped into six species (A−F). In normal in-
dividuals HAdV infections may present in various 
ways, affecting mainly the respiratory and intes-
tinal tract. Generally, these HAdV infections are 
well controlled by the innate and adaptive im-
mune system. The incidence of HAdV infections 
is higher in paediatric than in adult SCT recip-
ients, which might be related to the high expo-
sure to HAdV at young age, while HAdV-specif-
ic immunity has still to be mounted. The highest 
incidence of HAdV infections following SCT was 
found in children receiving a T-cell depleted graft 
and/or a graft of another than an HLA-genotyp-
ically identical related donor [1].
HAdV infections are not easily diagnosed and the 
development of a severe infection cannot be pre-
dicted by standard culture techniques. Similar to 
what has been demonstrated for several human 
herpes viruses, it was ﬁ rst shown several years ago 
that the appearance of HAdV DNA in serum pre-
ceded the development of a severe or fatal HAdV 
infection [2]. In subsequent retrospective as well 
as prospective studies evidence has been provid-
ed that monitoring of serum/plasma by real-time 
quantitative PCR (RQ-PCR) is a sensitive tool 
for the recognition of patients at risk of a poten-
tially fatal infection.[3–5] In addition, evidence 
has been provided that quantiﬁ cation of HAdV 
DNA is instrumental to make decisions on clin-
ical intervention, and to accurately monitor the 
response to antiviral therapy.
Several antiviral drugs (esp. ribavirin and cidofo-
vir) are being used to treat HAdV infections and 
variable efﬁ cacy has been reported. Susceptibility 
of clinical isolates to both antiviral drugs has been 
demonstrated in vitro. However, in the case of rib-
avirin susceptibility in vitro was restricted to sub-
group C viruses only [6]. Reports on the possi-
ble clinical efﬁ cacy of the drugs are often biased 
because of the heterogeneity of the patients and 
the lack of information about the level of simul-
taneous immune reconstitution. In our experi-
ence, ribavirin, when started in the early phase 
of viraemia, lacks the potential to effectively con-
trol disseminating HAdV (including subgroup 
C) infections [7]. In the case of cidofovir treat-
ment, temporary control of HAdV dissemination 
has been observed. In our experience, persistent 
control and subsequent clearance of HAdV infec-
tion in cidofovir treated patients has only been 
documented in those SCT recipients with stable 
lymphocyte reconstitution.
AIM
To analyse data in the ﬁ eld of diagnosis and treat-
ment of human adenovirus infection following 
allogeneic haematopoietic stem cell transplan-
tation.
MATERIALS AND METHODS
References were retrieved using the online 
database of the National Library of Medicine 
(PubMed; http://www.ncbi.nlm.nih.gov/PubMed). 
Terms used included: human adenovirus infec-
tion, allogeneic HSCT. The retrieved references 
were supplemented by references from the au-
thor’s own database.
RESULTS
Data from several retrospective and prospective 
studies have demonstrated that lymphocyte re-
covery is essential for the elimination of HAdV 
infection [8,9]. Low lymphocyte counts at the 
onset of infection were predictive of HAdV vi-
raemia. Survival of patients with HAdV viraemia 
was associated with an increase in lymphocyte 
counts during the ﬁ rst weeks after infection. In 
these patients, HAdV-speciﬁ c CD4+ T cell re-
sponses, as well as increases in titres of neutral-
izing antibody, were detected after clearance of 
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HAdV. Notably, in a signiﬁ cant number of pa-
tients lymphocyte recovery during HAdV infec-
tion and subsequent clearance was exclusively 
represented by expansion of NK cells (Verhoeven 
et al, manuscript submitted). These NK cells dis-
played an activated phenotype indicating that the 
NK cells might have contributed to the control 
of HAdV infection.
DISCUSSION
Based on current knowledge, boosting of immunity 
by tapering of immunosuppression or infusion of 
lymphocytes from the donor seems to be an essen-
tial element in the treatment of patients at risk of 
HAdV viraemia. Obviously, infusion of unmanip-
ulated donor lymphocytes will bear a signiﬁ cant 
risk of inducing serious graft-versus-host disease 
(GvHD). To lower the risk of alloreactivity, infu-
sion of allodepleted donor T cells has been studied 
in HLA-mismatched haploidentical SCT, although 
so far with limited efﬁ cacy against HadV infection 
[10]. Enrichment for HAdV-speciﬁ c T cells using 
in vitro culture systems appears to be a promising 
and feasible alternative approach. Recently, sev-
eral of these methods have been reported. These 
include the generation of HAdV speciﬁ c T cells 
using 1) HAdV lysate [11], 2) genetically modi-
ﬁ ed antigen-presenting cells expressing several vi-
ral epitopes including HAdV [12], and 3) a pool 
of conserved HAdV peptides [13]. Clinical expe-
rience with the ﬁ rst two methods seems promis-
ing. We are currently preparing the clinical use of 
HAdV-speciﬁ c T cells obtained after enrichment 
by the peptide stimulation procedure. In addition 
to the adoptive transfer of HAdV-speciﬁ c T cells it 
cannot be excluded that infusion of puriﬁ ed NK 
cells may exert a beneﬁ cial antiviral effect without 
the concomitant risk of inducing GvHD.
Similar to what has been reported for human 
herpes viruses, monitoring of HAdV infection by 
RQ-PCR analyses on serum/plasma samples seem 
to be a reliable and sensitive tool to identify indi-
viduals at risk for progressive infection.
CONCLUSIONS
Data from several retrospective and prospective 
studies have demonstrated that lymphocyte re-
covery is essential for the elimination of HAdV 
infection. Simultaneous analysis of lymphocyte 
reconstitution in these patients will further im-
prove the identiﬁ cation of individuals that will re-
quire and beneﬁ t most from the aforementioned 
immunotherapeutic interventions.
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